Clinical Trials for Mesothelioma Patients—Sorafenib, Pemetrexed, and Cisplatin

Read about a current clinical trial about the use of Sorafenib, Pemetrexed, and Cisplatin for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Purpose and Rationale:

Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with pemetrexed and cisplatin may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib when given together with pemetrexed and cisplatin in treating patients with advanced solid tumors.

Phase, Condition and Intervention:

Phase I; Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Prostate Cancer, Sarcoma; Drug: cisplatin, Drug: pemetrexed disodium, Drug: sorafenib tosylate

Study Type and Design:

Interventional treatment

Official Title:

Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.